Form 4: Avadel Director Sells Shares, Options in Alkermes Acquisition

Avadel Pharmaceuticals director Mark Anthony McCamish disposed of all his direct and indirect ordinary shares and stock options as part of Alkermes plc's acquisition of Avadel.

Summary

• Director Mark Anthony McCamish reported the disposition of Avadel Pharmaceuticals plc securities on February 12, 2026.
• The transactions occurred as part of the consummation of the acquisition of Avadel Pharmaceuticals plc by Alkermes plc via a scheme of arrangement.
• Each outstanding Avadel Ordinary Share was converted into $21.00 in cash and a non-transferable contingent value right (CVR) for a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones.
• Restricted Stock Awards vested in full at the Effective Time and were treated in the same manner as Ordinary Shares.
• Stock options were canceled and exchanged for cash (equal to the product of the number of shares subject to the option multiplied by the excess of the $21.00 Cash Consideration over the option's exercise price) and one CVR per underlying share.
• McCamish disposed of 22,000 directly owned Ordinary Shares and 67,025 indirectly owned Ordinary Shares held by McCamish Charitable Remainder Trust.
• He also disposed of multiple tranches of stock options, totaling 291,000 underlying Ordinary Shares, with exercise prices ranging from $4.79 to $16.32.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for Avadel shareholders, providing a definitive cash exit with potential for additional value through the CVR, reflecting the successful completion of a strategic acquisition.

Positives

• The acquisition by Alkermes plc provides a clear exit strategy and immediate liquidity for Avadel shareholders through a fixed cash consideration of $21.00 per share.
• Shareholders retain potential upside through a Contingent Value Right (CVR) of $1.50 per share, contingent on future milestones.
• Restricted Stock Awards and stock options held by the reporting person vested fully and were monetized as part of the transaction, benefiting equity holders.

Negatives

• Avadel Pharmaceuticals plc will no longer be an independent publicly traded entity, removing its stock from the market.
• The full $1.50 per share CVR payment is not guaranteed, as it is contingent upon the achievement of specific milestones, introducing an element of uncertainty.

Risks

• The contingent value right (CVR) payment of $1.50 per share is not guaranteed and is dependent on the achievement of certain specified milestones.

Future Outlook

The filing indicates the completion of Avadel Pharmaceuticals plc's acquisition by Alkermes plc, meaning Avadel will no longer operate as an independent public entity. The future outlook for former Avadel shareholders includes the potential for an additional $1.50 per share via CVRs, contingent on specific milestones.

Management Comments

• Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ('Issuer'), nominal value $0.01 per share ('Ordinary Shares'), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the 'Transaction Agreement') by and between Issuer and Alkermes plc ('Parent'), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the 'Scheme') pursuant to which Parent acquired Issuer.
• Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the 'Effective Time'), each outstanding Ordinary Share was converted into $21.00 in cash (the 'Cash Consideration') and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a 'CVR').
• Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a 'Restricted Stock Award'). Pursuant to the Transaction Agreement, at the Effective time, each Restricted Stock Award that was outstanding immediately prior to the Effective Time vested in full and was treated in the manner described in footnote 1.
• Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an 'Option') as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

Industry Context

StockSavvy.ai notes that pharmaceutical industry mergers and acquisitions are common strategies for larger companies like Alkermes to expand their product pipelines or market share, often involving a mix of cash and contingent value rights to manage deal risk and incentivize future performance. This particular transaction represents the successful completion of such a strategic move.

Comparison to Industry Standards

• The use of a contingent value right (CVR) in M&A transactions, such as the $1.50 per share CVR in this deal, is a common mechanism in the pharmaceutical and biotech sectors. For example, Pfizer's acquisition of Array BioPharma included CVRs tied to drug approval milestones.
• The cash consideration of $21.00 per share, combined with a CVR, is a standard structure for providing immediate liquidity while retaining potential upside for target company shareholders, similar to how some biotech acquisitions are structured to account for pipeline assets.

Management Changes

Corporate Governance

Related Party Transactions

• Shares held by McCamish Charitable Remainder Trust, of which the Reporting Person and his spouse are income beneficiaries. The Reporting Person disclaims beneficial ownership except to the extent of his and his spouse's pecuniary interest therein.

Stakeholder Impact

• Shareholders: Received $21.00 cash per share and a CVR for potential additional $1.50 per share, providing liquidity and potential upside.
• Employees (with Restricted Stock/Options): Benefited from full vesting and monetization of their equity awards.
• Company (Avadel): Ceased to exist as an independent public entity, integrated into Alkermes plc.

Next Steps

• Former Avadel shareholders will receive the $21.00 cash consideration per share.
• Former Avadel shareholders will hold CVRs, which may lead to an additional $1.50 per share payment upon achievement of specified milestones.
• Avadel Pharmaceuticals plc will cease to be a publicly traded company.

Key Dates

Recommendation

The company, Avadel Pharmaceuticals plc, has been acquired by Alkermes plc. As of February 12, 2026, each outstanding Avadel Ordinary Share was converted into $21.00 in cash and a contingent value right. Therefore, there is no longer a public market for Avadel shares, and current holders would have their shares converted, effectively a 'sell' of their equity position in Avadel.

Keywords

Avadel Pharmaceuticals, AVDL, Alkermes, Acquisition, Merger, Form 4, Insider Transaction, Stock Options, Contingent Value Right, CVR, Scheme of Arrangement